Table .
Patient Characteristics of Cases and Controls (Matched on Age, Sex, Race, and Body Mass Index)
| Controls (n=2173) | Type 2 NSTEMI (n=579) | P value | |
|---|---|---|---|
| Age, y | 70±14 | 71±15 | |
| Body mass index | 29±8 | 29±8 | |
| Sex | |||
| Male | 1231 (57%) | 326 (56%) | |
| Female | 942 (43%) | 253 (44%) | |
| Race and ethnicity | |||
| Asian | 89 (4%) | 27 (5%) | |
| Black | 606 (28%) | 164 (28%) | |
| Hispanic | 225 (10%) | 61 (11%) | |
| Other | 136 (6%) | 36 (6%) | |
| White | 1117 (51%) | 291 (50%) | |
| Payment source | 0.011 | ||
| Medicare/Title 18 | 932 (43%) | 228 (39%) | |
| Medicaid/Title 19 | 177 (8%) | 73 (13%) | |
| Private insurance | 387 (18%) | 93 (16%) | |
| VA/CHAMPVA/Tricare/Self‐Pay/Other/Unknown | 137 (6%) | 34 (6%) | |
| More than 1 | 540 (25%) | 151 (26%) | |
| Past medical history | |||
| Cancer | 324 (15%) | 95 (16%) | 0.322 |
| Chronic kidney disease | 386 (18%) | 176 (30%) | <0.001 |
| COPD | 288 (13%) | 95 (16%) | 0.051 |
| Coronary artery disease | 296 (14%) | 135 (23%) | <0.001 |
| Diabetes | 862 (40%) | 244 (42%) | 0.254 |
| Heart failure | 371 (17%) | 173 (30%) | <0.001 |
| Hypertension | 1559 (72%) | 468 (81%) | <0.001 |
| Smoking | 150 (7%) | 47 (8%) | 0.275 |
| Pre‐admission vitals | |||
| Systolic BP pre‐admission | 133±25 | 131±30 | 0.056 |
| Diastolic BP pre‐admission | 75±15 | 75±19 | 0.739 |
| Heart rate pre‐admission | 90±19 | 95±22 | <0.001 |
| Temperature pre‐admission | 99±1.6 | 99±1.8 | 0.556 |
| Oxygen saturation pre‐admission | 94±5 | 94±5.7 | 0.432 |
| Outpatient medications | |||
| Anticoagulation therapy | 358 (17%) | 94 (17%) | 0.937 |
| Antihyperglycemic therapy | 658 (31%) | 160 (30%) | 0.521 |
| Antihypertensive therapy | 1454 (68%) | 400 (74%) | 0.017 |
| Antiplatelet therapy | 788 (36%) | 250 (43%) | 0.002 |
| Immunosuppressive therapy | 287 (13%) | 79 (14%) | 0.641 |
| Lipid‐lowering therapy | 1067 (50%) | 287 (53%) | 0.131 |
Data are displayed as: n (column percent), mean±SD. BP indicates blood pressure; CHAMPVA, Civilian Health and Medical Program of the Department of Veterans Affairs; COPD, chronic obstructive pulmonary disease; NSTEMI, non–ST‐segment–elevation myocardial infarction; and VA, Veterans Affairs.